牛牛AI助理已提取核心訊息
On January 9, 2024, Panbela Therapeutics, Inc. received comments from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, which was initially filed on January 4, 2024. The SEC conducted a limited review and requested amendments to the registration statement, specifically asking Panbela Therapeutics to quantify the volume of Class E, Class F, and Pre-Funded Warrants on the cover page and to disclose the termination date of the offering. The SEC reminded the company of its responsibility for the accuracy and adequacy of disclosures. Panbela Therapeutics, which has engaged Roth Capital Partners as its placement agent in a best efforts offering, is expected to respond by amending the registration statement and providing the requested information. The SEC indicated that further comments may follow after reviewing the amendments and responses provided by Panbela Therapeutics.
On January 9, 2024, Panbela Therapeutics, Inc. received comments from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, which was initially filed on January 4, 2024. The SEC conducted a limited review and requested amendments to the registration statement, specifically asking Panbela Therapeutics to quantify the volume of Class E, Class F, and Pre-Funded Warrants on the cover page and to disclose the termination date of the offering. The SEC reminded the company of its responsibility for the accuracy and adequacy of disclosures. Panbela Therapeutics, which has engaged Roth Capital Partners as its placement agent in a best efforts offering, is expected to respond by amending the registration statement and providing the requested information. The SEC indicated that further comments may follow after reviewing the amendments and responses provided by Panbela Therapeutics.
2024年1月9日，Panbela Therapeutics, Inc.收到了美國證券交易委員會（SEC）對其最初於2024年1月4日提交的S-1表格註冊聲明的評論。美國證券交易委員會進行了有限的審查，並要求對註冊聲明進行修改，特別要求Panbela Therapeutics在封面上量化E類、F類和預融資認股權證的數量，並披露發行的終止日期。美國證券交易委員會提醒該公司對披露的準確性和充分性負責。Panbela Therapeutics已聘請Roth Capital Partners作爲其配售代理人，以盡最大努力進行發行，預計將通過修改註冊聲明並提供所需信息來做出回應。美國證券交易委員會表示，在審查了Panbela Therapeutics提供的修正案和答覆後，可能會發表進一步的評論。
2024年1月9日，Panbela Therapeutics, Inc.收到了美國證券交易委員會（SEC）對其最初於2024年1月4日提交的S-1表格註冊聲明的評論。美國證券交易委員會進行了有限的審查，並要求對註冊聲明進行修改，特別要求Panbela Therapeutics在封面上量化E類、F類和預融資認股權證的數量，並披露發行的終止日期。美國證券交易委員會提醒該公司對披露的準確性和充分性負責。Panbela Therapeutics已聘請Roth Capital Partners作爲其配售代理人，以盡最大努力進行發行，預計將通過修改註冊聲明並提供所需信息來做出回應。美國證券交易委員會表示，在審查了Panbela Therapeutics提供的修正案和答覆後，可能會發表進一步的評論。
有用
沒用